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Ovarian cancer is the most lethal gynecologic malignancy, with
an estimated 14,030 deaths expected from the disease in the United
States in 2013.1 The standard therapy for women with advanced
ovarian cancer is cytoreductive surgery followed by platinum-based
chemotherapy. While this approach results in high response rates
(80%), the majority of patients unfortunately experience recurrence
within 5 years. Therefore, it is of great importance to develop new
regimens that will improve the duration of remission and ultimately
prevent relapse.
Bevacizumab is a recombinant, humanized, monoclonal immu-
noglobulin G antibody that binds to and inactivates the biologic
activity of vascular endothelial growth factor A (VEGF-A) and was
the ﬁrst anti-VEGF agent to be approved by the United States
Food and Drug Administration for the treatment of cancer. A
mechanism of action is that it suppresses tumor growth by inhib-
iting neovascularization.2,3 Moreover, VEGF inhibition has been
demonstrated to directly affect the structure and function of tumor
vessels so as to improve the penetration of drugs into tumors,
possibly leading to more efﬁcient delivery of chemotherapeutic
agents to their targets.3 Bevacizumab is currently labeled for treat-
ment in patients with metastatic nonesmall-cell lung cancer,
glioblastoma, colorectal cancer, and renal cell cancer. Preliminary
data suggested that VEGF was particularly important in the pro-
gression of ovarian carcinoma, and multiple early studies showed
single-agent responses.4-6 This led to several large studies both in the
primary and recurrent settings. Here, we will summarize the existing
randomized data from 4 studies on the use of bevacizumab in
epithelial ovarian cancer (EOC) and then offer an opinion regarding
its inclusion in the treatment algorithm for women with advanced
disease.Memorial Sloan-Kettering Cancer Center, New York, NY
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The Gynecology Oncology Group (GOG) 218 trial investigated
the addition of bevacizumab at 15 mg/kg every 3 weeks to standard
carboplatin and paclitaxel chemotherapy given every 3 weeks in a
randomized, double-blinded, 3-arm, placebo-controlled study.7 The
trial enrolled 1873 patients with stage III-IV EOC who had residual
disease after primary debulking surgery. Patients were randomized
to receive either 6 cycles of carboplatin plus paclitaxel plus placebo,
with placebo continued for cycles 7 to 22 every 3 weeks; 6 cycles
of carboplatin plus paclitaxel plus bevacizumab, with placebo
continued for cycles 7 to 22 every 3 weeks; or 6 cycles of carboplatin
plus paclitaxel plus bevacizumab, with bevacizumab continued for
cycles 7 to 22 every 3 weeks. Progression-free survival (PFS) was the
primary endpoint of the trial, and a statistically signiﬁcant beneﬁt
was seen in the bevacizumab maintenance arm compared with
the control arm (14.1 months vs. 10.3 months; P < .001). How-
ever, no beneﬁt was seen when bevacizumab was given only with
chemotherapy (11.2 months vs. 10.3 months; P ¼ .16). No dif-
ference in overall survival (OS) was detected at the time of PFS
analysis. The ability to detect a difference in OS was potentially
confounded by the fact that patients in both groups went on to
receive treatment with multiple subsequent regimens, including
bevacizumab and other antiangiogenic agents. Finally, the FACT-O
TOI (Trial Outcome Index of the Functional Assessment of Cancer
Therapy e Ovary) was used to assess quality of life (QoL) peri-
odically throughout the study, and showed that QoL was higher
among those receiving standard chemotherapy alone, but that there
was no difference among groups in QoL during the bevacizumab
maintenance period.8 However, the authors acknowledge that
attending clinic every 3 weeks to receive a placebo may have had
a negative impact on QoL. Thus, the results may have under-
estimated the QoL difference associated with bevacizumab in this
latter portion of the trial (ie, if the comparison was every-3-week
bevacizumab compared with observation only).
The ICON 7 (International Collaboration on Ovarian Neo-
plasms) trial investigated the addition of bevacizumab at 7.5 mg/kg
every 3 weeks (50% of the dose used in GOG 218) to standard
carboplatin and paclitaxel followed by maintenance bevacizumab for2212-9553/$ - see frontmatter ª 2014 Elsevier Inc. All rights reserved.
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12 subsequent cycles or until progression of disease.9 The trial
enrolled 1528 women, 70% (1069 of 1528 patients) of whom had
stage IIIC or stage IV EOC, and randomized them to receive
standard carboplatin and paclitaxel or carboplatin and paclitaxel
plus bevacizumab given concurrently every 3 weeks for 6 cycles and
continued for 12 additional cycles or until progression of disease. At
36 months, the PFS was statistically signiﬁcantly greater in patients
who received bevacizumab than in those who did not (21.8 vs.
20.3 months; P ¼ .004). An updated and preplanned analysis at
42 months found that the beneﬁt of bevacizumab therapy was
greater in high-risk disease (stage IV or stage III with > 1 cm
residual disease), with PFS of 18.1 months in the bevacizumab
group versus 14.5 months in the control arm and respective median
OSs of 36.6 and 28.8 months. An additional interesting ﬁnding
was that the maximum PFS beneﬁt was seen at 12 months, the time
at which maintenance bevacizumab was stopped, and had dis-
appeared by 24 months. This ﬁnding suggests that prolonged
bevacizumab therapy (beyond 12 months, if patients are respond-
ing) might improve outcomes as well. Finally, QoL questionnaires
completed by patients in the bevacizumab group and the standard
chemotherapy group both at week 18 (the end of chemotherapy)
and at week 54 (the end of continuation bevacizumab) showed a
small but statistically signiﬁcant (P < .0001) decrement in QoL in
the bevacizumab arm compared with that of patients who received
standard chemotherapy.10
In contrast to GOG 218 and ICON 7, which evaluated
the addition of bevacizumab to primary therapy, the OCEANS
(Ovarian Cancer Study Comparing Efﬁcacy and Safety of
Chemotherapy and Anti-Angiogenic Therapy in Platinum-Sensitive
Recurrent Disease) study evaluated the addition of bevacizumab to
the treatment of platinum-sensitive EOC at the time of disease
recurrence.11 Investigators randomly assigned 484 patients with
platinum-sensitive recurrent EOC (deﬁned as recurrence  6
months after frontline platinum-based therapy) to receive gemcita-
bine and carboplatin plus either bevacizumab or placebo for 6 to 10
cycles, with bevacizumab or placebo continued until disease pro-
gression. PFS for the bevacizumab arm was superior to that in the
placebo arm, with median PFS of 12.5 months versus 8.4 months
(P < .001). The OS data is not yet mature, but may ultimately be
difﬁcult to evaluate, given that a number of patients from both arms
went on to receive subsequent chemotherapy (89.3%), which
included antiangiogenic therapy in approximately 40%.
AURELIA was the ﬁrst randomized controlled trial to evaluate
the combination of bevacizumab and chemotherapy in platinum-
resistant EOC.12 Investigators randomized patients with
platinum-resistant EOC who had received fewer than 3 prior
anticancer regimens and who had no history of bowel obstruction,
abdominal ﬁstula, or clinical or radiographic evidence of rec-
tosigmoid involvement to receive chemotherapy alone or chemo-
therapy plus bevacizumab. Chemotherapy options included weekly
paclitaxel, topotecan given on days 1, 8, and 15 of a 4-week cycle, or
monthly liposomal doxorubicin. Patients were stratiﬁed by chemo-
therapeutic agent, prior antiangiogenic treatment, and treatment-free
interval (< 3 months vs. 3-6 months). The primary endpoint
was PFS, and secondary endpoints included overall response rate
(ORR), OS, QoL, and safety and tolerability. The median PFS was
6.7 months in patients who received bevacizumab-containingregimens, compared with 3.4 months in patients receiving chemo-
therapy alone; the difference in PFS was statistically signiﬁcant
(P < .001) regardless of age, progression-free interval, presence or
absence of ascites, or type of chemotherapy given. The ORR was
also statistically signiﬁcantly different (P < .001), with a response
seen in 30.9% of patients who received bevacizumab-containing
regimens versus 12.6% in those receiving chemotherapy alone.
Data on OS is not yet mature but is expected to be available this year.
Based on the results of ICON 7 and GOG 218, bevacizumab was
approved by the European Medicines Agency for use in both ﬁrst-
line adjuvant treatment of advanced EOC and for ﬁrst recurrence
after initial chemotherapy. To date, it has not been approved by the
United States Food and Drug Administration for either of these
indications. Where does bevacizumab belong in the armamentarium
of treatment for ovarian cancer?
In our opinion, the available data suggests the increasing efﬁcacy
of bevacizumab as a patient moves along in the disease course or
develops more advanced disease. The least beneﬁt appears to be in
patients who receive it as part of primary therapy and who are
optimally debulked. In these patients, the PFS advantage is modest,
no overall survival beneﬁt has been seen, and the risk-to-beneﬁt
ratio is not decidedly in favor of its use. In GOG 218, hyperten-
sion of grade 2 or higher was signiﬁcantly more common with
bevacizumab than placebo, rates of gastrointestinal perforation and
ﬁstula in the 2 bevacizumab groups were almost twice those in the
control group (albeit low), and fatal adverse events were reported in
14 of 608 patients in the bevacizumab-throughout group compared
with 6 in 601 of the control group.7 In ICON 7, hypertension of
grade 2 or higher was seen in 136 (18%) of patients treated with
bevacizumab, thromboembolic events of grade 3 or higher were seen
in 51 (7%) of patients treated with bevacizumab, and 10 (1%)
patients treated with bevacizumab suffered from GI perforation.
There were 4 treatment-related deaths in the bevacizumab group
(1 each from GI perforation, intracerebral hemorrhage, recurrent
bowel perforation, and neutropenic sepsis).9 In addition, the
magnitude of the PFS beneﬁt is small when compared with the
duration of expected OS, and additional responses may be seen with
further therapy. Finally, there is no evidence that bevacizumab
treatment in these patients alters the proportion of patients who will
ultimately relapse. Based on the preplanned subgroup analysis in
ICON 7, if there is a clinically meaningful beneﬁt in patients
receiving primary therapy including bevacizumab, it is found in
those with more advanced or suboptimally debulked disease. In the
latest version of the NCCN Guidelines for Ovarian Cancer, adju-
vant bevacizumab-containing regimens such as those used in ICON
7 and GOG 218 receive a category 3 recommendation, reﬂecting
the fact that there is disagreement among panel members with re-
gard to their use.
What about in recurrent disease? In general, in platinum-sensitive
disease, platinum-based combination chemotherapy leads to
ORRs from 30% to 60%. However, in this group of patients, the
OCEANS data showed that in patients randomized to platinum-
based chemotherapy plus bevacizumab (n ¼ 242), the median
PFS was > 50% greater than that in in the patients receiving
gemcitabine and carboplatin alone (n ¼ 242), and the ORR was
higher (79% vs. 57%; P < .001). However, there were also higher
rates of treatment discontinuation for adverse events (23% vs. 5%),Clinical Ovarian and Other Gynecologic Cancer December 2012 - 49
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50 -including higher rates of serious hypertension, proteinuria, and
nonecentral nervous system bleeding. Interim data reported at the
Society of Gynecologic Oncology annual meeting in 2012 revealed
that at a median follow-up of 35 months, the 2 arms had similar
OS (33 vs. 35 months).13 QoL data were not explicitly evaluated
in the study, and as the authors point out, it is difﬁcult to evaluate
OS data in this group because of crossover, as many patients sub-
sequently went on to receive multiple other therapies. GOG 213 is
a randomized phase III study for women with recurrent platinum-
sensitive ovarian cancer, evaluating OS in patients treated with
carboplatin and paclitaxel with or without bevacizumab. This trial
and others like it will better deﬁne the role of bevacizumab in
recurrent platinum-sensitive disease. In the recurrent platinum-
sensitive setting, where disease progression is nearly universal and
the goal of therapy is to keep the patient free from symptoms of
disease and treatment, the risk-to-beneﬁt ratio shifts more toward
considering the use of bevacizumab.
In platinum-resistant recurrent disease, in which responses to
other regimens are not as robust as those in platinum-sensitive
recurrence, bevacizumab assumes a more important role. In the
preliminary results of AURELIA, not only was the median PFS in
the patients who received bevacizumab-containing regimens nearly
double that of the patients receiving chemotherapy alone, but the
ORR was also signiﬁcantly improved (P < .001) by the addition of
bevacizumab, regardless of the chemotherapeutic regimen used.
Among those who received paclitaxel, the ORR was 52% with
bevacizumab versus 29% without; in the topotecan group, the ORR
was 23% with bevacizumab versus 3% without; and among those
who received liposomal doxorubicin, the ORR was 18% with
bevacizumab versus 8% without.14 We await further follow-up to
determine the impact of bevacizumab treatment on OS in this
group, but these results, if supported in the ﬁnal analysis, are the
strongest in support of adding bevacizumab to the treatment of
patients with ovarian cancer.
Conclusion
In summary, we believe that bevacizumab deﬁnitely has a role in
the treatment of patients with ovarian cancer. It should be available
for treatment as is any other agent with deﬁnite activity along the
disease course. In our opinion, the data is weakest for its inclusion in
the primary treatment of patients with optimally debulked disease.
The results of the primary treatment studies could be discussed
with patients having suboptimally debulked or stage IV disease,Clinical Ovarian and Other Gynecologic Cancer December 2012with potential risks and known beneﬁts (modest PFS) addressed.
The data grows stronger in support of offering bevacizumab in the
recurrent platinum-sensitive setting and is particularly robust in the
platinum-resistant setting, based on the preliminary data reported
with a near doubling of response rate and PFS in the latter.
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